Nafarelin is a potent agonistic analog of gonadotropin-releasing hormone (GnRH). Nafarelin has been used in the treatments of central precocious puberty and endometriosis.

The global Nafarelin market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Nafarelin volume and value at global level, regional level and company level. From a global perspective, this report represents overall Nafarelin market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Pfizer
Shanghai Soho-Yiming Pharmaceuticals
CPC Scientific
Hangzhou Longshine Bio-Tech
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Nasal Spray
Freeze-dried Powder

Segment by Application
Central Precocious Puberty
Endometriosis